FDAnews Device Daily Bulletin

St. Jude Results Reflect Troubled 2012, But Atrial Fib Sales Shine

Feb. 1, 2013
A A
St. Jude Medical expects less than half of its 2013 income to come from cardiac rhythm management (CRM) sales, due to an ongoing global slowdown in the market for cardiac devices, CEO Dan Starks said in a Tuesday earnings call. This will mark the first time since the 1990s that CRM has contributed less than half of the company’s revenue.
Devices & Diagnostics Letter